The United States Pharmacopeia (USP) Expert Committee on General Chapters - Dosage Forms announced a major revision of general chapter Tablet Breaking Force <1217>. Comments can be submitted until October 15, 2016. Read more about the planned revision of USP general chapter <1217>.
To put the EU Medical Devices (93/42/EEC and 90/385/EEC) in concrete terms, the EU issues so-called MEDDEV documents. In this context, the document MEDDEV 2.7/1 revision 4 entitled "Clinical Evaluation: A Guide for Manufacturers and Notified Bodies under Directives 93/42/EEC and 90/385/EEC" has been newly published. Comprising 65 pages, the document is very extensive and describes requirements for the clinical evaluations of medical devices in Europe.
With a draft document made up of 66 pages, the WHO intends to provide support regarding the introduction and implementation of regulations with regard to medical devices, including in vitro diagnostic medical devices (IVDs). The document is a revised draft whose first version - however - hasn't been published. The document history shows that the revision had become necessary as the first draft was too complicated. What does the second draft contain?
With its new draft guidance on human factors and usability requirements, the MHRA is giving greater emphasis to design process in the development of medical devices and combination products - particularly with regard to the increasing complexity of these products. Find out more about the MHRA's expectation for medical devices and combination products in terms of design process.
The EMA has recommended that medicines manufactured by the U.S. company Pharmaceutics International Inc. should no longer be available in the EU. This follows the issuance of two Non-Compliance Reports for two sites of the US based company.
It has been a hot inspection summer. FDA Warning Letters and EU Non-Compliance Reports seem to increase at the moment. It is worrying that the GMP non-compliance issues apparently get more serious than in the past. But what is the reason for the increasing GMP non-compliances?
In pharmaceutical water systems, ozone is an effective method to keep microbiological contamination under control. In the course of cold production (and storage) of WFI, which will be allowed as of April 2017, ozone will play an even bigger role. When ozone is being used to sanitize a piping system, its effect has to be verified. Learn more about the classification of Ozone Measurement in Piping Systems.
Last year, a public consultation was launched on a draft revised Annex 17 on Real Time Release Testing. Deadline for comments was 11 December 2015. Now, the feedback from the various stakeholders was published.
A Danish pharmaceutical manufacturer has received a so-called "Untitled Letter" from the FDA after an inspection at his production site in Denmark. The letter was issued because of deviations from diverse GMP rules. Read more about the definition of an Untitled Letter and the GMP violations identified.
The US Food and Drug Administration (FDA) finalized its revised regulations governing drug establishment registration and drug listing. Read more about the requirements for foreign and domestic establishment registration and listing for human drugs, including drugs that are regulated under a biologics license application, and animal drugs.
With this news we inform you about recent developments concerning EudraLex Volume 9 - Guideline on good pharmacovigilance practices (GVP). Read more about the revisions of GVP Module VI and IX (including Addendum) and published finals of GVP Module VIII and P.II on biological medicinal products.
Relating to the fast developments in Zika Virus transmisions, the FDA now published a guidance for Industry with Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components.
In addition to the existing guidance on donor eligibility, the FDA published a new guidance document on " Determining Donor Eligibility for Autologous Donors of Blood and Blood Components Intended Solely for Autologous Use"
The United States Pharmacopeia (USP) is currently undertaking further steps towards a comprehensive analytical lifecycle approach by publishing a draft of a new General Chapter <1210> Statistical Tools for Procedure Validation and two Stimuli Articles regarding Analytical Target Profile and Analytical Control Strategy in Pharmacopeial Forum. Read more about the life cycle concept for analytical procedures.
The US Food and Drugs Administration (FDA) has issued a Warning Letter to a British API manufacturer. They criticized cross contamination by penicillin products, deviations regarding pharmaceutical water and foreign particles in the product. Read more about the major deviations in this Warning Letter.
The FDA has set the focus of its inspections on data integrity for quite some time already. The most recent Warning Letter addressed to a Chinese API manufacturer dated August 2016 clearly concentrates on the topic data integrity. Please find out more about the current FDA Warning Letter in this News.
The ECA's Visual Inspection Group has developed a new document with answers to frequently asked questions. This new Q&A document is now available for download on the Group's website. Read more about frequently asked questions in the visual inspection.
In the Pharmacopeial Forum 42(4) [Jun-Jul 2016] a revised draft of general chapter <771> Ophthalmic Products-Quality Tests has been published for comment. Read more about the draft USP chapter <771> describing quality tests for opthalmic dosage forms.